What 'Not for Human Consumption' Really Means

The "not for human consumption" label — and its variant "not for human use" — is a regulatory classification, not a warning about purity and not an indication of toxicity. It appears on any material catalogued as RUO (Research Use Only): it means the compound has not completed the clinical approval processes that a regulatory body requires before classifying a molecule as a medicine. The label describes the product's legal framework, not its physicochemical properties.

Why that label exists

Research peptides and approved medicines operate under different regulatory frameworks. For a molecule to be sold as a drug — in the United States, Argentina or any comparable jurisdiction — it must complete a long cycle of preclinical and clinical trials, undergo review by a regulatory authority, and receive explicit approval for each therapeutic indication. That process typically takes ten to fifteen years.

RUO materials occupy a different category: molecules of scientific interest available to laboratories and researchers working at stages before that approval, or for whom an approved drug is not the end goal. The "not for human consumption" label marks that distinction. It tells the buyer that the material was not evaluated by the FDA, ANMAT or any equivalent authority for use in people.

What the label does not say — and this is where the most common misunderstanding lives — is anything about the compound's quality.

Purity and regulatory classification are separate variables

The confusion arises because the label sounds like a health warning. It is not.

A research peptide can reach 99.893 % purity by HPLC — the result that Janoshik Analytical returned for the retatrutide lot analysed on 13 April 2026, available in PeptoClinic's quality section — and still carry "not for human consumption." That figure tells you what fraction of the vial's contents is the declared compound, measured by a precise analytical technique. The label tells you under which legal framework that vial is sold.

An approved medicine can, by contrast, meet looser purity specifications and circulate legally for clinical use because it completed the required registration processes.

The two variables are independent. A researcher evaluating a lot reviews both: the certificate of analysis to verify purity and compound identity, and the regulatory framework to understand in which context they can work with the material. Neither replaces the other.

What a well-documented RUO material includes

The document that distinguishes a serious supplier from one that is not is not the vial label: it is the Certificate of Analysis (COA). This is a report signed by the analytical laboratory that performed the measurement, and it contains information no label can carry.

A legitimate COA states:

• The compound name and its task number in the issuing laboratory's system.
• The technique used for the analysis, typically reverse-phase HPLC.
• The purity result as a percentage.
• The declared content on the label versus the actual content found in the analysis.
• The date of the analysis.
• The laboratory name and the signature of the person certifying the result.

The four reports published by PeptoClinic correspond to analyses performed by Janoshik Analytical. Two of them allow direct verification on the laboratory's platform using the task number. The full detail for each compound — result, task number and verification method — is in PeptoClinic's quality section.

The task number is the most important field in a COA for a researcher: it lets you open the original report in the laboratory's system and confirm that the document in hand has not been altered.

What RUO classification means in practice

A material catalogued as RUO is appropriate for in vitro research — cell culture assays, receptor binding studies, biochemical characterisation — for work in animal models under the applicable ethical protocols at each institution, and for synthesis projects, comparative analysis and development of analytical methods.

It has not been evaluated for any use in humans or companion animals. That evaluation does not exist because it was never performed, not because it was performed and failed. The distinction matters for reading the label correctly — and for understanding what it does not say.

The PeptoClinic catalogue lists the compounds available under that classification. Each is quoted as reference material for research, accompanied by the corresponding lot documentation. Shipment to Argentina and other regional destinations is available; details are in the shipping section.

For laboratory research only

PeptoClinic Research Supply provides research peptides exclusively for laboratory use, in vitro research and preclinical studies. The materials available are not approved and are not suitable for human or veterinary consumption, are not medicines, are not dietary supplements, and have not been evaluated by any health authority — not ANMAT, not the FDA, and not any equivalent — for diagnosing, treating or preventing any condition. Enquiries about administration protocols for people are declined.

Why the label matters when choosing a supplier

That a supplier includes the label correctly says something about how they understand the framework they operate in. Its absence — or its presence alongside therapeutic indications for people — is a more meaningful warning sign than the label itself: it indicates the supplier is not working within the legal framework that protects both the buyer and the activity.

What does allow objective evaluation of a supplier are the questions a COA makes answerable:

• Did the supplier publish laboratory reports with a task number verifiable on the issuing laboratory's site?
• Is the laboratory that issued the COA independent of the supplier?
• Does the date on the analysis correspond to the lot being dispatched?

Those three questions have verifiable answers. PeptoClinic's quality documentation explains what accompanies each shipment and how to confirm each report directly in Janoshik Analytical's system.